Su HY, Hsu YC. Patients with cirrhosis during the COVID-19 pandemic: Current evidence and future perspectives . World J Clin Cases 2021; 9(13): 2951-2968 [PMID: 33969082 DOI: 10.12998/wjcc.v9.i13.2951]
Corresponding Author of This Article
Hsu YC, MD, Staff Physician, Department of Emergency Medicine, E-DA Hospital, I-Shou University, No. 1 Yida Road, Jiao-su Village, Yanchao District, Kaohsiung 82445, Taiwan. yinchou0406@gmail.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. May 6, 2021; 9(13): 2951-2968 Published online May 6, 2021. doi: 10.12998/wjcc.v9.i13.2951
Patients with cirrhosis during the COVID-19 pandemic: Current evidence and future perspectives
Hung-Yuan Su, Yin-Chou Hsu
Hung-Yuan Su, Yin-Chou Hsu, Department of Emergency Medicine, E-DA Hospital, I-Shou University, Kaohsiung 82445, Taiwan
Hung-Yuan Su, Yin-Chou Hsu, School of Chinese Medicine for Post Baccalaureate, I-Shou University, Kaohsiung 82445, Taiwan
Author contributions: Hsu YC designed the study; Su HY and Hsu YC reviewed the literature and drafted the manuscript; both authors have read and approved the final manuscript.
Conflict-of-interest statement: Authors have nothing to declare.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Hsu YC, MD, Staff Physician, Department of Emergency Medicine, E-DA Hospital, I-Shou University, No. 1 Yida Road, Jiao-su Village, Yanchao District, Kaohsiung 82445, Taiwan. yinchou0406@gmail.com
Received: January 4, 2021 Peer-review started: January 4, 2021 First decision: January 23, 2021 Revised: February 5, 2021 Accepted: March 25, 2021 Article in press: March 25, 2021 Published online: May 6, 2021 Processing time: 107 Days and 20 Hours
Core Tip
Core Tip: Several studies have addressed the impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in patients with cirrhosis. The presence and stage of cirrhosis is correlated with the development of severe coronavirus disease-2019 (COVID-19), COVID-19-related adverse outcomes, and mortality. It remains unclear whether SARS-CoV-2 infection is a trigger of acute decompensation or acute-on-chronic liver failure in cirrhotic patients based on the current evidence. There is still no clearly proven effective pharmacological treatment for cirrhotic patients with COVID-19. Clinicians should maintain standard cirrhosis care, defer unnecessary liver-specific procedures and have a low threshold for admission if cirrhotic patients are infected with SARS-CoV-2.
